Drugmaker with rare disease work · based in San Francisco Bay Area, United States · founded 2018 · apeiron-bio.com
Apeiron Therapeutics (also known as GT Apeiron) is a clinical-stage biopharmaceutical company developing biomarker-driven cancer therapeutics using AI-guided drug design. The company's lead program GTA182 targets MTAP-deleted cancers and presented first-in-human Phase 1 data in December 2025. Note: this is a separate entity from Apeiron Biologics (Austrian, acquired by Ligand Pharmaceuticals), which developed dinutuximab beta for neuroblastoma.
Apeiron Therapeutics Inc clinical trials
We did not find active Apeiron Therapeutics Inc trials for the rare diseases we track on ClinicalTrials.gov right now.
More about Apeiron Therapeutics Inc
The clinical trials section below shows active and recruiting rare disease studies sponsored by Apeiron Therapeutics Inc, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Apeiron Therapeutics Inc is headquartered in San Francisco Bay Area, United States, founded in 2018. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Apeiron Therapeutics Inc's own site is apeiron-bio.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Questions about Apeiron Therapeutics Inc
Apeiron Therapeutics (also known as GT Apeiron) is a clinical-stage biopharmaceutical company developing biomarker-driven cancer therapeutics using AI-guided drug design. The company's lead program GTA182 targets MTAP-deleted cancers and presented first-in-human Phase 1 data in December 2025. Note: this is a separate entity from Apeiron Biologics (Austrian, acquired by Ligand Pharmaceuticals), which developed dinutuximab beta for neuroblastoma.
Apeiron Therapeutics Inc is a diversified pharmaceutical company headquartered in San Francisco Bay Area, United States, founded in 2018. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 0 active rare disease programs. Many of its rare disease treatments hold orphan drug designations from the FDA.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Apeiron Therapeutics Inc, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
None that we track as of November 2026. No Apeiron Therapeutics Inc label in the FDA's openFDA database matches a rare disease on Trial Friend, which usually means the company has no approved product yet or its approved drugs are for common conditions.
In development: the trials list on this page shows what Apeiron Therapeutics Inc is recruiting for now, and the FDA calendar lists any application once a decision date is public.
Apeiron Therapeutics Inc was founded in 2018 and is headquartered in San Francisco Bay Area, United States. The company has been active for 8 years.